Page last updated: 2024-12-06

n-nitrosoheptamethyleneimine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID30360
CHEMBL ID165634
CHEBI ID183735
SCHEMBL ID105009
MeSH IDM0042642

Synonyms (40)

Synonym
20917-49-1
1-nitrosoazocane
nitrosoheptamethyleneimine
n-nitrosoazacyclooctane
ccris 467
brn 1562771
azocine, octahydro-1-nitroso-
nhmi
n-nitrosoheptamethyleneimine
octahydro-1-nitrosoazocine
n-nitrosooktahydroazocin [czech]
nitroso-heptamethylenimin [german]
FT-0691140
1-nitroso-azocane
CHEMBL165634
N0446
heptamethylenenitrosamine
CHEBI:183735
NCGC00249045-01
tox21_302962
dtxcid601039
dtxsid1021039 ,
NCGC00256350-01
cas-20917-49-1
NCGC00258985-01
tox21_201434
0vcf90a5fp ,
n-nitrosooktahydroazocin
unii-0vcf90a5fp
5-20-04-00167 (beilstein handbook reference)
nitroso-heptamethylenimin
SCHEMBL105009
1-nitrosoazocane #
RCFKQVLHWYOSFF-UHFFFAOYSA-N
heptamethylenimine, 1-nitroso-
n-nitrosoheptamethylenimine
Q27231152
T72064
BS-43945
EN300-7356893

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The carcinogen dose-response relationship observed in situ was also seen in the transplanted organs."( Tumor development in organ transplants obtained from carcinogen-exposed rats.
Nettesheim, P; Yarita, T, 1979
)
0.26
"N-Nitrosoheptamethyleneimine (NHMI) was given by gastric intubation, at a dosage of 10 mg/kg body weight twice weekly for 5-20 weeks, to F344 rats bearing subcutaneous tracheal transplants."( Epithelial lesions induced by N-nitrosoheptamethyleneimine in host and transplanted rat tracheas.
Griesemer, RA; Kendrick, J; Nettesheim, P; Taylor, HW, 1976
)
1.99
"A dose-response study of the carcinogenicity of nitrosoheptamethyleneimine (N-HEP) in inbred F344 male and female rats was performed by administration of the nitrosamine at several concentrations in drinking water to groups of 20 rats."( Dose-response studies with nitrosoheptamethyleneimine and its alpha-deuterium-labeled derivative in F344 rats.
Davies, TS; Lijinsky, W; Reuber, MD; Riggs, CW, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrosamineN-Nitroso amines, compounds of the structure R2NNO. Compounds RNHNO are not ordinarily isolable, but they, too, are nitrosamines. The name is a contraction of N-nitrosoamine and, as such, does not require the N locant.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency48.45900.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency68.58960.000221.22318,912.5098AID1259243
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.96220.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.66260.000229.305416,493.5996AID743075; AID743079
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.30600.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID226732The compound was modelled in silico for carcinogenic potency; + = Carcinogen1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (80.00)18.7374
1990's3 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]